NFE2L2 and neoplasm: With this information, we evaluated the anticancer activity of an AIM, RTA 405 (CDDO-Ethyl Amide) [8;11;41–47] in tumor cell lines where NRF2 activity could be induced (ie, those with a wild-type KEAP1-NRF2 axis) compared with tumor cell lines where NRF2 activity was already at its maximal level (ie, elevated NRF2 activity due to loss of KEAP1 function).